The PRISM 2 consortium consists of world leading preclinical and clinical experts that form a highly collaborative team with an existing track record of fruitful EU-funded research projects. This includes the successful implementation and completion of the PRISM project, which the PRISM 2 project is based on.
With 12 partners in Europe and 2 partners in the United States of America (USA), the PRISM 2 consortium builds a strong multidisciplinary team of researchers from academic research institutions, pharmaceutical companies, and small and medium-sized enterprises (SMEs). The broad spectrum of expertise in the fields of neuroscience, psychiatry, neurology, and (epi-)genetics accelerates the knowledge transfer between academia, industry, and the general public. The team is spearheaded by the project coordinator Prof. Dr. Martien Kas (RUG) and the project leader Dr. Hugh Marston (BI).
The overarching goal of PRISM 2 is to advance research and create real-life benefit for patients suffering from neuropsychiatric disorders, especially Alzheimer Disease (AD), Schizophrenia (SZ), and Major Depressive Disorder (MDD).
University of Groningen
Groningen, The Netherlands
Boehringer Ingelheim International GmbH
Centro de Investigación Biomédica en Red
Cohen Veterans Bioscience Inc.
New York, NY, USA
concentris research management gmbh
European College Of Neuropsychopharmacology
Utrecht, The Netherlands
Leiden University Medical Center
Leiden, The Netherlands
Paramus, NJ, USA
Radboud University Medical Center
Nijmegen, The Netherlands
University of Bologna
VU University Medical Center Amsterdam
Amsterdam, The Netherlands